Location History:
- Waco, TX (US) (2005 - 2008)
- McGregor, TX (US) (2015 - 2016)
Company Filing History:
4 out of 25 
4 out of 194 
Years Active: 2005-2016
Title: **Innovations of Charles Manly Garner, III: A Pioneering Inventor in Vascular Targeting Agents**
Introduction
Charles Manly Garner, III, based in Waco, TX, is a distinguished inventor with a notable portfolio of four patents. His innovative work primarily focuses on developing novel compounds that serve as effective vascular targeting agents for treating various cancers and diseases related to unwanted neovascularization. Garner’s contributions reflect significant advancements in medical science, particularly in the realm of cancer treatment.
Latest Patents
Garner's latest patents revolve around functionalized stilbene derivatives, which are groundbreaking as vascular targeting agents. These novel stilbenoid compounds, along with their prodrug forms, demonstrate potent efficacy in treating solid tumor cancers. Specifically, the compounds display tubulin-binding properties, making them structurally analogous to combretastatin A-1 and combretastatin A-4. This innovative approach highlights the potential of these stilbenoid compounds not only in oncology but also in addressing retinal neovascularization, showcasing their versatility in medicinal applications.
Career Highlights
Throughout his career, Charles Garner has made substantial contributions while working for renowned organizations such as Oxigene, Inc. and Baylor University. His tenure in these companies has helped shape his research focus and propelled his work into the realm of practical applications that can benefit patients suffering from severe medical conditions.
Collaborations
In his journey as an inventor, Garner has had the privilege of collaborating with esteemed colleagues such as David J Chaplin and Robert Ronald Kane. These partnerships have undoubtedly enriched his research and allowed for a more significant impact on the scientific community.
Conclusion
Charles Manly Garner, III stands out as a pivotal figure in the realm of medical innovations. His contributions to the development of vascular targeting agents represent a critical advancement in cancer treatment and the management of neovascular diseases. As he continues to innovate, the implications of his work promise to improve patient outcomes and inspire further research in the field of medicinal chemistry.